These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26188238)

  • 21. (131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome.
    Pathirana AA; Vinjamuri S; Byrne C; Ghaneh P; Vora J; Poston GJ
    Eur J Surg Oncol; 2001 Jun; 27(4):404-8. PubMed ID: 11417988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Selective therapeutic embolization in malignant insulinoma].
    Civera Andrés M; Real Collado JT; Martínez Usó I; Ampudia Blasco FJ; Carmena Rodríguez R
    Rev Clin Esp; 2000 Oct; 200(10):548-50. PubMed ID: 11153238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
    Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
    Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of intractable hypoglycemia with Yttirum-90 radioembolization in a patient with malignant insulinoma.
    Chandra P; Yarandi SS; Khazai N; Jacobs S; Umpierrez GE
    Am J Med Sci; 2010 Nov; 340(5):414-7. PubMed ID: 20724903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Embolization of the liver in the management of metastatic carcinoid tumors.
    Mårtensson H; Nobin A; Bengmark S; Lunderquist A; Owman T; Sandén G
    J Surg Oncol; 1984 Nov; 27(3):152-8. PubMed ID: 6208426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of disseminated midgut carcinoid tumours.
    Ahlman H; Wängberg B; Jansson S; Stenqvist O; Geterud K; Tylén U; Caidahl K; Scherstén T; Tisell LE
    Digestion; 1991; 49(2):78-96. PubMed ID: 1724766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
    Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
    Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of cytoreductive hepatic surgery as an adjunct to the management of metastatic neuroendocrine carcinomas.
    Hodul P; Malafa M; Choi J; Kvols L
    Cancer Control; 2006 Jan; 13(1):61-71. PubMed ID: 16508628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
    Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
    Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metastatic neuroendocrine hepatic tumors: resection improves survival.
    Musunuru S; Chen H; Rajpal S; Stephani N; McDermott JC; Holen K; Rikkers LF; Weber SM
    Arch Surg; 2006 Oct; 141(10):1000-4; discussion 1005. PubMed ID: 17043278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obstructive sleep apnoea syndrome (OSAS) as a complication of carcinoid syndrome treated successfully by hepatic artery embolization.
    Milkiewicz P; Olliff S; Johnson AP; Elias E
    Eur J Gastroenterol Hepatol; 1997 Feb; 9(2):217-20. PubMed ID: 9058639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatic artery embolisation--new approach for treatment of malignant carcinoid syndrome.
    Jermendy G; Kónya A; Kárpáti P
    Dtsch Z Verdau Stoffwechselkr; 1986; 46(2):130-6. PubMed ID: 2424713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoglycemia induced by long-acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor.
    Unek IT; Celtik A; Yener S; Yavuzsen T; Alacacioglu A; Cokmert S; Oztop I; Demirkan B; Dicle O; Sagol O; Bekis R; Yilmaz U
    J BUON; 2009; 14(1):135-8. PubMed ID: 19365885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Symptomatic treatment of the malignant carcinoid syndrome with octreotide].
    Alberts AS; Falkson G
    S Afr Med J; 1989 Jan; 75(1):30-1. PubMed ID: 2911781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma.
    Healy ML; Dawson SJ; Murray RM; Zalcberg J; Jefford M
    Intern Med J; 2007 Jun; 37(6):406-9. PubMed ID: 17535385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroendocrine Tumors.
    Basuroy R; Srirajaskanthan R; Ramage JK
    Gastroenterol Clin North Am; 2016 Sep; 45(3):487-507. PubMed ID: 27546845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Management of digestive system carcinoid tumors and carcinoid syndrome].
    Mondragón Sánchez RJ; Castillero Pinilla C; Saldívar Moreno C; Oñate Ocaña LF; Ruiz Molina JM; Aiello Crocifoglio V
    Rev Gastroenterol Mex; 1998; 63(4):204-10. PubMed ID: 10319670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel agents in gastroenteropancreatic neuroendocrine tumors.
    Stevenson R; Libutti SK; Saif MW
    JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Carcinoid tumors].
    Tóth M; Prónai L; Németh AM; Tulassay Z
    Orv Hetil; 2002 May; 143(19 Suppl):1087-92. PubMed ID: 12063867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.